Table 8.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Kidney-Pancreas Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		493	661	748	919	860	853	972	941	914	891
Tx with Antirejection Treatments		323	430	385	550	528	266	222	217	192	170
Antibodies	Category Usage	72.8%	72.6%	60.5%	43.5%	24.8%	45.5%	41.9%	40.1%	43.8%	29.4%
	ALG	25.4%	18.4%	16.4%	7.3%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.9%	1.4%	0.5%	3.6%	6.1%	16.5%	8.1%	6.0%	3.1%	1.2%
	NRATG/NRATS	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.5%	0.0%	0.0%	0.0%
	OKT3	61.0%	64.7%	54.5%	38.0%	19.7%	31.6%	33.3%	23.5%	22.4%	11.8%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.4%	13.4%	17.2%	16.5%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	1.8%	1.4%	2.1%	1.2%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.6%	0.6%
Corticosteroids	Category Usage	85.1%	86.7%	85.2%	60.9%	46.2%	64.7%	80.2%	78.3%	82.8%	88.2%
	Steroids	85.1%	86.7%	85.2%	60.9%	46.2%	64.7%	80.2%	78.3%	82.8%	88.2%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.